However, the consistently higher expression of CD33 and CD123 on AML blasts compared to normal hematopoietic stem cells suggests potential therapeutic benefits with minimal impact on healthy bone marrow function [274]. The gene discussed is CD33; the disease is acute myeloid leukemia.